Albireo Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss
May 9, 2019 7:40 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($1.39), $0.07 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $970 thousand.
For Albireo, 2019 is focused on advancing toward potential approval and launch of odevixibat in its first... More
